Tadalafil
- Product NDC
- 50436-0370
- Requested package NDC
- 50436-0370-1
- 11-digit product format
- 504360370
- Labeler code
- 50436
- Product ID
- 50436-0370_6a89c13d-8ba2-491f-a3a7-432a9967b6b3
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- Tadalafil
- Dosage form
- TABLET, FILM COATED
- Route
- ORAL
- Labeler
- Unit Dose Services
- Application
- ANDA209167
- Marketing category
- ANDA
- Marketing start
- 2019-03-27
- Marketing end
- 0000-00-00
- Substance
- TADALAFIL
- Active strength
- 5 mg/1
- Pharmacologic classes
- Phosphodiesterase 5 Inhibitor [EPC], Phosphodiesterase 5 Inhibitors [MoA]
- NDC exclude flag
- No
- Listing certified through
- 2023-12-31
- Current FDA listing
- Historical FDA.report record
NDC auxiliary status#
Explicit status records from FDA unfinished, excluded, and compounder auxiliary files. Absence of a row is not itself a regulatory status. Browse every current auxiliary row, including rows without a usable NDC. · Browse every captured source and parsed snapshot.
| Dataset | Scope | Product NDC | Package NDC | Code | Status | Reporting period | Source date |
|---|---|---|---|---|---|---|---|
| excluded package | package | 50436-0370 | 50436-0370-1 | I | Inactivated by FDA | 2026-07-31 |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A209167-001 | TADALAFIL | TADALAFIL | 2.5MG | TABLET / ORAL | AB1 | 2019-03-26 | |
| A209167-002 | TADALAFIL | TADALAFIL | 5MG | TABLET / ORAL | AB1 | 2019-03-26 | |
| A209167-003 | TADALAFIL | TADALAFIL | 10MG | TABLET / ORAL | AB1 | 2019-10-23 | |
| A209167-004 | TADALAFIL | TADALAFIL | 20MG | TABLET / ORAL | AB1 | 2019-03-26 |
Therapeutic equivalence codes#
| Application-product | TE code |
|---|---|
| A209167-001 | AB1 |
| A209167-002 | AB1 |
| A209167-003 | AB1 |
| A209167-004 | AB1 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-01 22:54:32 | 2026-06 | A209167-001 | TADALAFIL | 2.5MG | TABLET / ORAL | AB1 | 2019-03-26 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | A209167-002 | TADALAFIL | 5MG | TABLET / ORAL | AB1 | 2019-03-26 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | A209167-003 | TADALAFIL | 10MG | TABLET / ORAL | AB1 | 2019-10-23 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | A209167-004 | TADALAFIL | 20MG | TABLET / ORAL | AB1 | 2019-03-26 | a50c72e98297… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-08-01 22:54:32 | 2026-06 | A209167-001 | AB1 | 1 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | A209167-002 | AB1 | 1 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | A209167-003 | AB1 | 1 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | A209167-004 | AB1 | 1 | a50c72e98297… |
openFDA label cross-check#
Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report. Every label matching the complete exact-identifier union is deduplicated and paginated below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Tadalafil | TADALAFIL | Bryant Ranch Prepack | 07567ae5-7345-4ab1-9b2c-c586c4da0427 | 2026-06-24 | Warnings, Adverse reactions | 209167 ANDA209167 |
| Tadalafil | TADALAFIL | Bryant Ranch Prepack | aa8d165b-0c7d-497a-b56a-7c62ebc0a5d2 | 2026-05-13 | Warnings, Adverse reactions | 209167 ANDA209167 |
| Tadalafil | TADALAFIL | Bryant Ranch Prepack | f8def23c-55ea-4796-9735-dbcb25104835 | 2026-05-13 | Warnings, Adverse reactions | 209167 ANDA209167 |
| Tadalafil | TADALAFIL | Accord Healthcare Inc. | eedf3ad9-7d40-496d-b1a9-6200010c18e1 | 2026-04-16 | Warnings, Adverse reactions | 209167 ANDA209167 |
| Tadalafil | TADALAFIL | Preferred Pharmaceuticals Inc. | affacb88-4af3-4ce9-961b-7fc37b169e9a | 2026-01-12 | Warnings, Adverse reactions | 209167 ANDA209167 |
| Tadalafil | TADALAFIL | Northwind Health Company, LLC | f3092f5a-b976-91ab-e053-2995a90a9b50 | 2026-01-01 | Warnings, Adverse reactions | 209167 ANDA209167 |
| Tadalafil | TADALAFIL | Northwind Health Company, LLC | f317fe1e-d7c4-fb8b-e053-2a95a90a5445 | 2026-01-01 | Warnings, Adverse reactions | 209167 ANDA209167 |
| Tadalafil | TADALAFIL | NuCare Pharmaceuticals,Inc. | cf35291b-b05b-1182-e053-2995a90a8dee | 2025-02-10 | Warnings, Adverse reactions | 209167 ANDA209167 |
| Tadalafil | TADALAFIL | NuCare Pharmaceuticals,Inc. | 9f83ea2e-8ee8-ab6d-e053-2995a90a1e96 | 2024-06-20 | Warnings, Adverse reactions | 209167 ANDA209167 |
| Tadalafil | TADALAFIL | NuCare Pharmaceuticals,Inc. | a0acad71-8ae3-2827-e053-2995a90a20b3 | 2024-06-20 | Warnings, Adverse reactions | 209167 ANDA209167 |
| Tadalafil | TADALAFIL | Proficient Rx LP | 7a105ef9-7129-4ce1-bd8d-ae316bf348e2 | 2022-11-01 | Warnings, Adverse reactions | 209167 ANDA209167 |
| Tadalafil | TADALAFIL | Proficient Rx LP | b539e862-d5d4-4989-a3dd-1eba66285d53 | 2022-05-01 | Warnings, Adverse reactions | 209167 ANDA209167 |
| Tadalafil | TADALAFIL | Proficient Rx LP | 31c05a53-7282-46d0-81bd-108defe6fb38 | 2022-04-01 | Warnings, Adverse reactions | 209167 ANDA209167 |
| Tadalafil | TADALAFIL | Proficient Rx LP | 6fa9d4fa-86c9-4791-b28b-78e8b9341cea | 2022-04-01 | Warnings, Adverse reactions | 209167 ANDA209167 |
| Tadalafil | TADALAFIL | Asclemed USA, Inc. | aba646fe-70c2-1abb-e053-2995a90aa16d | 2022-01-28 | Warnings, Adverse reactions | 209167 ANDA209167 |
DailyMed Product Concepts#
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| b90b74cb-f6c8-3798-d11c-73b8768b278a | Product name | 8 | 20250317 |
| 0fe0157c-95a7-4870-ae64-de9f3fa874ae | Product name | 1 | 20250227 |
| 20ae0006-d78c-4dba-9e3e-6ae424841903 | Product name | 1 | 20250127 |
| b86a08b7-54cc-440b-ad4a-3e530ccd8324 | Product name | 6 | 20230421 |
| 7a02e74a-2844-42af-84a8-96bae57351cf | Product name | 1 | 20230313 |
| 928d249c-35c3-4d88-a9ef-cf2f2e31b96f | Product name | 1 | 20220706 |
FDA-Initiated Inactive NDC Indexing#
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 50436-0370-1 | Tadalafil | 30 in 1 BOTTLE | TABLET, FILM COATED | 30 | 4 | |
| 50436-0370-2 | Tadalafil | 90 in 1 BOTTLE | TABLET, FILM COATED | 90 | 4 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 50436-0370 | TADALAFIL TABLET, FILM COATED [UNIT DOSE SERVICES] | 4 | Legacy NDC, 2 package rows | 20220922_e3aafacc-c392-4a0c-82ed-ef139e363732.zip |
DailyMed RxNorm Mappings#
| RxCUI | RxNorm string | TTY | DailyMed | SPL version |
|---|---|---|---|---|
| 403957 | tadalafil 5 MG Oral Tablet | PSN | e3aafacc-c392-4a0c-82ed-ef139e363732 | 4 |
| 403957 | tadalafil 5 MG Oral Tablet | SCD | e3aafacc-c392-4a0c-82ed-ef139e363732 | 4 |
Packages#
| Package NDC | 11-digit format | Description | Marketing start | Marketing end | Sample | Exclude flag | Status |
|---|---|---|---|---|---|---|---|
| 50436-0370-1 | 50436037001 | 30 TABLET, FILM COATED in 1 BOTTLE (50436-0370-1) | 2021-11-01 | 0000-00-00 | No | No | Current |